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Role of Integrated 18-Fluorodeoxyglucose Position Emission
Tomography-Computed Tomography in Patients
Surveillance after Multimodality Therapy of Malignant
Pleural Mesothelioma
Carol Tan, FRCS (CTh),* Sally Barrington, MD,† Sheila Rankin, FRCR,‡ David Landau, FRCR,§
John Pilling, FRCS (CTh),* James Spicer, PhD,§ Paul Cane, FRCPath,
and Loïc Lang-Lazdunski, PhD*
Introduction: To investigate the role of 18-fluorodeoxyglucose
positron emission tomography-computed tomography (18-FDG-
PET-CT) in the surveillance of patients after multimodality treat-
ment of malignant pleural mesothelioma.
Methods: Retrospective study of patients who had chemotherapy,
radical surgery, extrapleural pneumonectomy or pleurectomy/decor-
tication, and radiotherapy for mesothelioma in our unit. PET-CT
was performed after multimodality therapy to evaluate response to
treatment or when disease recurrence was suspected. 18-FDG-PET
scans were acquired from skull base to upper thigh with low-dose
CT scans for attenuation correction and image fusion.
Results: Forty-four patients had extrapleural pneumonectomy (21)
or pleurectomy/decortication (23) between January 2004 and July
2008. Twenty-five patients had PET-CT performed after multimo-
dality therapy. This was performed in 11 patients in whom disease
recurrence was suspected at a median of 9 (range, 6–16) months
after treatment. PET-CT correctly diagnosed recurrent disease in
eight patients and missed microscopic recurrence in one. Surveil-
lance PET-CT was performed in 14 asymptomatic patients at a
median of 11 (range, 7–13) months after treatment. It showed
unsuspected recurrences in four patients. The standard uptake value
max of recurrent mesothelioma was 8.9  4.0 (4–18.4). PET-CT
had a sensitivity of 94%, a specificity of 100%, and the positive and
negative predictive values of 100 and 88%, respectively.
Conclusions: 18-FDG-PET-CT is useful in diagnosing disease re-
currence after multimodality therapy for malignant pleural mesothe-
lioma. We propose a prospective study to fully assess its value in
this group of patients.
Key Words: Malignant mesothelioma, PET-CT, Multimodality
therapy, Surveillance.
(J Thorac Oncol. 2010;5: 385–388)
The incidence of malignant pleural mesothelioma (MPM)in Great Britain and Europe is rising as predicted1,2 but
treatment options remain limited and controversial. The
chance of cure is rare with most deaths occurring within 1 to
2 years of diagnosis. Radical surgery or extrapleural pneu-
monectomy (EPP) on its own has not been associated with
any demonstrable increase in survival,3 and it is now most
often being offered with chemotherapy and radiotherapy.4,5 A
less-extensive surgical resection, also known as pleurectomy/
decortication (P/D) may be performed to strip away the tumor
without removing the underlying lung.6 The objective of
radical P/D is to achieve complete macroscopic clearance of the
tumor with resection of pericardium and diaphragm, if neces-
sary. However, in patients with more extensive disease, P/Dmay
only involve removal of the tumor bulk to allow re-expansion of
the underlying lung and relieve symptoms of breathlessness and
pain.7 Only a small proportion of patients with mesothelioma are
deemed suitable candidates for multimodality therapy that in-
cludes chemotherapy, radical surgery, and radiotherapy.
Positron emission tomography (PET) with 18-fluoro-
deoxyglucose (FDG) has established an important role in
the diagnosis and staging of MPM,8,9 and therefore, it is a
useful tool in the assessment of patients when considering
multimodality therapy. It may be useful to help character-
ize pleural lesions, direct biopsy, and assess the extent of
tumor involvement, in particular to detect extrathoracic
metastasis. Integrated 18-FDG-PET-CT combines ana-
tomic and metabolic information in a single imaging pro-
cedure and has been shown to be a reliable tool in the
staging and assessment of patients with MPM who are
candidates for radical treatment.10 Preliminary reports us-
ing 18-FDG-PET-CT to monitor tumor response to che-
motherapy and radiotherapy have been published.11–13 The
use of PET/PET-CT to identify recurrent disease after
radical surgery has not been well studied.14 The aim of this
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study was to investigate the potential role of PET-CT using
18-FDG in the surveillance of patients who have under-
gone multimodality therapy for MPM.
PATIENTS AND METHODS
Patients with a diagnosis of MPM who have been
treated with chemotherapy, radical surgery, and radiotherapy
were identified retrospectively from our departmental data-
base. Radical surgery involved either EPP or P/D. Patients
undergoing EPP were given induction chemotherapy consist-
ing of three cycles of cisplatin and gemcitabine or pem-
etrexed. After EPP, they received radical hemithoracic radio-
therapy (54 Gy in 30 fractions). Those undergoing P/D
received adjuvant chemotherapy within 8 weeks of surgery
on the premise that induction chemotherapy can make P/D
technically more difficult. Adjuvant chemotherapy consisted
of four to six cycles of cisplatin and pemetrexed. In addition,
patients who underwent P/D had prophylactic radiotherapy to
wound and chest drain sites (21 Gy in three fractions).
All patients were followed up regularly in the outpa-
tient clinic till death. They were seen initially at 1 month after
surgery, then 3 to 6 monthly thereafter.
After multimodality therapy, PET-CT was performed
as part of routine surveillance. Patients were scanned in the
fasting state 90 minutes after injection of 350 MBq of FDG
on Discovery ST PET-CT cameras (General Electric Health-
case, Milwaukee, WI). Images were acquired from skull base
to upper thighs at 5 minutes per 15-cm bed position. Low-
dose noncontrast CT scans were performed for attenuation
correction and image fusion. Images were reconstructed
using iterative reconstruction. PET and CT datasets were
reported on a dedicated workstation by two independent
readers. In patients reported as having active tumor, a
region of interest was drawn around the tumor on the axial
plane with the “hottest” uptake to calculate the maximum
SUV (SUVmax) according to the formula:
Max SUV  maximum activity concentration (MBq/ml)
 body weight (g)/injected activity (MBq)
RESULTS
A total of 44 patients underwent multimodality therapy
between January 2004 and July 2008 for MPM. There were
40 men and four women and their median age was 62 years
(range, 45–74 years). EPP was performed in 21 patients and
P/D in 23. Twenty-six patients had right-sided disease and 18
had left-sided disease. All patients who had EPP and 14 who
had P/D had R0-R1 resection. Epithelioid mesothelioma was
confirmed histologically in 29 patients, biphasic in 13 pa-
tients, and sarcomatoid in two patients.
Twenty-five of 44 patients had PET-CT scans after
multimodality therapy. The remaining 19 consisted of pa-
tients who died unexpectedly after treatment, patients who
clearly had recurrence diagnosed on CT or who were referred
for radical surgery as a part of the Mesothelioma and Radical
Surgery trial15 but were then followed up with CT locally. A
few patients were too ill to travel to attend for a PET-CT
performed in London.
PET-CT was performed when disease recurrence was
suspected or as a part of routine surveillance. Disease recur-
rence was suspected clinically when patients exhibit symp-
toms of weight loss, cough, chest pain, or increasing breath-
lessness, or when there was a follow-up chest radiograph that
was abnormal or showed possible disease progression. In 11
patients, PET-CT was performed when disease recurrence
was suspected at a median of 9 (range, 6–16) months post-
operatively. PET-CT correctly identified recurrent disease in
eight patients but missed microscopic recurrence in one. Prior
CT scan was performed in six of the 11 patients, four of them
were felt to be diagnostic of recurrent disease. In the other two
patients, recurrent disease was suspected on CT scan but was not
diagnostic. A subsequent PET-CT confirmed local recurrent
disease was identified in one patient and in the other no evidence
of recurrence was found. The latter patient was diagnosed to
have constrictive pericarditis from which he later died.
The other 14 patients were asymptomatic and under-
went PET-CT as a part of surveillance at a median of 11
(range, 7–13) months postoperatively. PET-CT showed un-
suspected recurrence in nine patients. Eleven of the 14 pa-
tients had undergone prior CT scan, three of them were felt to
be diagnostic of recurrent disease. In six of the 11 patients, no
evidence of recurrent disease was seen on CT scan, but
PET-CT subsequently showed recurrence in four, all with
local intrathoracic disease. In addition, peritoneal disease was
also identified by PET-CT in two of the four patients. In two
of the 11 patients, CT scan was suspicious for recurrence, but
PET-CT showed no FDG uptake in these suspicious areas,
indicating no evidence of recurrent disease.
Patients with recurrence identified by PET-CT all had
local intrathoracic disease, but in addition, PET CT identified
recurrence in the contralateral lung in two patients, metastatic
peritoneal disease in four patients, bone metastasis in two
patients (Fig. 1), and metastasis to a supraclavicular node in
one patient.
PET-CT failed to identify recurrence in one patient who
had developed a small contralateral pleural effusion 12
months after left EPP. She went on to have video-assisted
thoracoscopy where multiple small nodules on the visceral
and parietal pleura were seen (Fig. 2). Biopsies confirmed
these to be recurrent mesothelioma.
The mean SUVmax of recurrent disease was measured
at 8.9  4.0 (range, 4–18.4). Histologic confirmation of
recurrent disease was obtained in all patients where recur-
rence was suspected on PET-CT. The absence of disease was
established by clinical and radiologic follow-up; mean fol-
low-up was 18 (range, 6 to 39) months. PET-CT correctly
identified recurrent mesothelioma in 17 of the 18 (sensitivity
94%) patients and correctly identified seven of the seven as
having no residual disease (specificity 100%). Positive and
negative predictive values were 100 and 88%, respectively.
Six of the seven patients with no disease seen on PET or
histologically are still alive. The other patient died 18 months
after EPP from constrictive pericarditis, confirmed at post-
mortem examination. Ten of the 17 patients with recurrent
disease identified by PET are still alive.
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When recurrent disease was identified by PET-CT,
patients were offered second-line chemotherapy with either
cisplatin and pemetrexed or single-agent vinorelbin. Re-
cently, patients have been offered enrolment into a phase I
trial of second-line sorafenib.
DISCUSSION
Response evaluation after surgery, chemotherapy, or
radiotherapy with CT scans can be challenging in MPM due
to its diffuse pattern of growth. Differentiation between
postoperative changes and disease recurrence is difficult us-
ing anatomic techniques alone. Integrated PET-CT enables
morphologic and metabolic information to be obtained at a
single scanning session. PET-CT with FDG, a glucose ana-
logue, relies on uptake of the tracer into cancer cells, which
have increased glucose transport and glucose turnover com-
pared with normal cells. Scar tissue that is metabolically
inactive does not take up FDG and thus can be differentiated
from recurrent disease. The uptake of FDG can also be
increased in inflammatory cells especially soon after surgery
or radiotherapy. In this series, patients were scanned at a
minimum of 6 months after surgery and 3 months after
radiotherapy and uptake within inflammatory tissue did not
result in “false positive” scans. Recurrent disease was able to
be discriminated from treatment-related changes.
Our patients were treated according to two different
protocols, with patients undergoing EPP receiving preopera-
tive chemotherapy and postoperative radical hemithorax ra-
diotherapy, and those undergoing P/D receiving adjuvant
chemotherapy and radiotherapy to wound and drain sites
only. After radical surgery, recurrence occurs locoregionally,
usually within the ipsilateral hemithorax in patients who have
undergone P/D and mainly in the contralateral hemithorax,
mediastinum, and peritoneal cavity in those who have under-
gone EPP.16–18 Because of the difference in the pattern of
relapse, the accuracy of PET-CT may be affected because it
may detect recurrence better at one site than another, e.g.,
extrathoracic sites compared with mediastinum.
Evaluation of mediastinal lymph nodes with CT alone
can be difficult as lymphadenopathy may be reactive after
multimodality therapy and small-volume peritoneal disease is
also difficult to detect on CT. We had performed initial CT
FIGURE 1. Spinal metastasis identi-
fied by 18-FDG PET CT in the T5
vertebral body at 8 months after left
EPP. Patient was complaining of
back pain.
FIGURE 2. Video-assisted thoracos-
copy showing small pleural deposits
in the contralateral hemithorax not
seen on 18-FDG-PET-CT.
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scan on 17 of our 25 patients who went on to have PET-CT
to clarify CT scan findings. In patients who were suspected to
have recurrent disease, we were more likely to proceed with
PET-CT without before CT scan. In our experience, we have
found that the accuracy of PET-CT in detecting mediastinal
recurrence can be affected by previous talc pleurodesis or
sarcoid-like reactive lymphadenopathy. However, PET-CT
has been particularly useful in detecting extrathoracic disease
such as subdiaphragmatic, gastric, celiac, hepatic, and
renal lymph nodes, although metastatic deposits need to be
5 to 10 mm in size to be resolved with PET.19 Where the
size of lymph nodes is noted to be within “normal” limits,
the ability to add metabolic information to conventional
imaging is helpful as a high SUV often reveals metastatic
spread. In our patients with FDG uptake in the supracla-
vicular or axillary nodes, ultrasound-guided biopsy con-
firmed the presence of metastatic disease. Similarly, pa-
tients with FDG uptake in gastric or celiac lymph nodes
underwent endoscopic ultrasound fine-needle aspiration to
confirm disease recurrence.
When recurrent disease is diagnosed, 85% of patients
die within 3 months.20 Early diagnosis of recurrence with
18-FDG-PET-CT allows patients to be offered further active
treatment such as second-line chemotherapy, novel cytostatic
agents, or vaccines currently being evaluated in clinical
trials.21,22 In our experience, we have noted that the second-
line options are less likely to be offered to patients who have
had EPP within the intensive multimodality therapy than
patients who have undergone P/D, as EPP patients are often
more frail at this stage.
PET-CT is increasingly being used for monitoring
tumor response to chemotherapy and radiotherapy, and there
is a growing evidence that therapy-induced changes in tumor
FDG uptake may predict response and patient outcome.23 A
high SUVmax in the tumor is associated with poor survival
and SUV analysis could potentially be used to select patients
with MPM for aggressive treatment with multimodality ther-
apy or for clinical trials of novel agents, such as antiangio-
genesis treatments. Benard et al.24 used a cut off SUV of two
to differentiate between benign and malignant disease at
presentation, reporting a sensitivity of 91% and a specificity
of 100%. The mean SUVmax of recurrent disease in our
study was 8.9 with a range of 4 to 18.4. A SUVmax above 4
seems to differentiate recurrence from postoperative change
in our patients, with a negative predictive value of 88% and
similar sensitivity and specificity.
Our preliminary experience in 25 patients suggests that
18-FDG-PET-CT could be a useful tool to identify recurrent
disease in patients who have undergone multimodality ther-
apy for malignant mesothelioma particularly when CT scan
has failed to discriminate or identify recurrence. We recog-
nize that this is a small retrospective study and the value of
PET-CT in this patient group should be assessed further in a
prospective study, with the first scan performed 6 months
after the completion of multimodality therapy, then yearly till
death. PET-CT should also be performed whenever disease
recurrence is suspected.
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